Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Efficacy and Safety Study of BMS-986142 in Patients with Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine whether the study drug, BMS-986142, is safe and effective in treating moderate to severe rhematoid arthritis in subjects with an inadequate response to methot...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study
To compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Safety, Efficacy and Dose response study of BMS-986001 in subjects with HIV-1 Infection who are treatment-naive
• To assess the efficacy of three doses of BMS-986001 by determining the proportion of subjects with plasma HIV-1 RNA < 50 c/mL as measured by PCR analyses at Week 24 • To assess the safety of three...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK PS Study. Revised Protocol 02 incorporating Protocol Amendment 09 and Administrative Letter 01 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (v1.0, dated 12-Sep-2008)
To compare the overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to sorafenib and receive brivanib plus best supportive care (BSC) to those receiving placeb...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women with Early Stage Breast Cancer Revised Protocol 02 incorporating Protocol Amendments 02 (version 1.0, dated 25-May-07) and 03 (version 1.0, dated 22-May-08) + Pharmacogenetics Blood Sample Amendment 01 - Site Specific (Version 1.0, dated 21-Dec-2006)
• To estimate the pCR rate of AC followed by ixabepilone relative to the pCR rate for AC followed by paclitaxel in women with early stage breast cancer. • To estimate the pCR rate of AC followed by ix...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Exemestane (Aromasin®) plus Dasatinib versus Exemestane plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer after Disease Progression on a Non-steroidal Aromatase Inhibitor (NSAI). + Administrative Letter 1 dated 18-Aug-2008; Revised Protocol 02 incorporating Administrative Letter 02 (dated 30-Nov-2009) and Protocol Amendment 02 (dated 06-Apr-2010)
To compare progression-free survival (PFS) distribution for exemestane plus dasatinib vs exemestane plus placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
An international study at different study sites testing the safety and effectiveness of a drug called BMS-986231 in the form of Intravenous Infusions for a duration of 48 hours in hospitalized patients whose heart is unable to pump sufficiently to maintain the blood flow their body needs to function well. Estudio internacional en diferentes centros para evaluar la seguridad y la eficacia de un medicamento llamado BMS-986231 que se administra como una infusion intravenosa durante 48 horas en pacientes hospitalizados cuyo corazón no es capaz de bombear la cantidad de sangre suficiente para mantener el flujo sanguineo que su cuerpo necesita para funcionar bien
The primary objective is to evaluate the effects of various doses of BMS-986231 compared to placebo on clinically relevant hypotension (defined by SBP < 90 mm Hg or symptoms of hypotension) El o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Open label study with Dasatinib in patients with Chronic Phase Chronic Myeloid Leukemia treated with Imatinib
To compare the rate of major molecular response (MMR) at 12 months after Day 1 initiation of first line treatment with imatinib, in patients randomized at month 3 to treatment with dasatinib 100mg QD...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer. Estudio fase II de Ixabepilona y Trastuzumab versus Docetaxel y Trastuzumab en mujeres con cáncer de mama localmente avanzado y/o mestatásico con sobresexpresión de Her2
To estimate the response rate for ixabepilone plus trastuzumab and the response rate for docetaxel plus trastuzumab in female subjects with Her2+ locally advanced and/or metastatic breast cancer not p...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Protocol AI463203: A Study of the Safety and Efficacy of Entecavir plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure
To describe the efficacy of the combination therapy of ETV plus TDF at 48 weeks of treatment, in control of viral load (HBV DNA < 50 IU/mL) in chronic HBV infected subjects who have failed previous tr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
4
5
6
7
8
9
10
11
12
13
Suivant